Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06219018 Not yet recruiting - Clinical trials for High Risk Human Papillomavirus

Effect of Honey For CIN II

HoneyForCIN2
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase inthe normalization of CIN II lesions compared to expectant management.

NCT ID: NCT06215846 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

NCT ID: NCT06212076 Not yet recruiting - Solid Tumor Clinical Trials

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Start date: February 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

NCT ID: NCT06211751 Not yet recruiting - Clinical trials for Hematologic Malignancy

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.

NCT ID: NCT06208657 Not yet recruiting - Childhood Cancer Clinical Trials

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A companion platform trial to test novel targeted agents based on the patient's tumor profile.

NCT ID: NCT06206915 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Study of XZ120 in Malignant Tumors

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.

NCT ID: NCT06202066 Not yet recruiting - Clinical trials for Malignant Solid Neoplasm

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Start date: July 15, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients with neuroendocrine tumors (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and is growing, spreading or getting worse (progressing). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Survivin, a protein, is expressed in 50% of patients that have neuroendocrine tumors and, is associated with poor outcomes. SVN53-67/M57-KLH peptide vaccine (SurVaxM) is a vaccine that has been shown to produce an immune system response against cancer cells that express a survivin and may block the growth of new tumor cells. Giving temozolomide with SurVaxM may kill more tumor cells in patients with progressing metastatic neuroendocrine tumors.

NCT ID: NCT06201884 Not yet recruiting - Surgery Clinical Trials

Efficacy of Adapted Physical Activity on a Walking Platform in Elderly Patients HOspitalized for Cancer Surgery

APPAHOCA-2
Start date: February 2024
Phase: Phase 2
Study type: Interventional

The aim of this study was to evaluate the efficacy of daily use of a walking platform to improve recovery of preoperative walking speed at hospital discharge following oncological surgery in patients aged 65 or older.

NCT ID: NCT06200116 Not yet recruiting - Clinical trials for Malignant Solid Neoplasm

Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning

Start date: August 1, 2024
Phase:
Study type: Observational

This study measures the utility of a novel artificial intelligence (AI) algorithm for performing auto-segmentation of computed tomography (CT) scans for radiation therapy planning.

NCT ID: NCT06199908 Not yet recruiting - Clinical trials for Advanced Solid Tumors

AMT-562 in Patients With Selected Advanced Solid Tumors

Start date: March 31, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.